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Abstract Human mitochondrial DNA (mtDNA) research
has entered a massively parallel sequencing (MPS) era,
providing deep insight into mtDNA genomics and molec-
ular diagnostics. Analysis can simultaneously include
coding and control regions, many samples can be studied in
parallel, and even minor heteroplasmic changes can be
detected. We investigated heteroplasmy using 16 different
tissues from three unrelated males aged 40–54 years at the
time of death. mtDNA was enriched using two independent
overlapping long-range PCR amplicons and analysed by
employing illumina paired-end sequencing. Point mutation
heteroplasmy at position 16,093 (m.16093T [ C) in the
non-coding regulatory region showed great variability
among one of the studied individuals; heteroplasmy
extended from 5.1 % in red bone marrow to 62.0 % in the
bladder. Red (5.1 %) and yellow bone marrow (8.9 %)
clustered into one group and two arteries and two aortas
from different locations into another (31.2–50.9 %), giving
an ontogenetic explanation for the formation of somatic
mitochondrial heteroplasmy. Our results demonstrate that
multi-tissue screening using MPS provides surprising data
even when there is a limited number (3) of study subjects
and they give reason to speculate that mtDNA hetero-
plasmic frequency, distribution, and even its possible role
in complex diseases or phenotypes seem to be
underestimated.
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Background
Mitochondria that host 37 genes within 16.6 kb of their
genome (mtDNA) are the power engines of the cell.
Mitochondrial DNA (mtDNA) gene regulation and repli-
cation start from the non-coding control region, D-loop,
that is 1,124 bp long from positions 16,024–576. The
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D-loop has three hypervariable regions (HVRI-III) and
contains 25 % of the variable sites, even though it
represents only 7 % of the total mtDNA length (Sosa
et al. 2012). Mitochondrial diseases associated with
mtDNA mutations and its phenotypic heterogeneity can
be explained by mtDNA heteroplasmy—the mixture of
more than one type of mtDNA at a cellular, tissue or
organism level. The 100-fold higher mutation rate of
mtDNA than nuclear DNA is caused by a combination
of oxidative microenvironment, lack of histones, and
rudimentary repair mechanisms, leading to mtDNA
mutation accumulation during aging. Although mtDNA
is maternally inherited in mammals, heteroplasmy levels
vary markedly between a mother and each of her off-
spring. This means that asymptomatic mothers with
medium to low heteroplasmy levels can have an affected
child with much higher levels of the same heteroplasmic
mutation ([30 %), which may cause a mitochondrial
disease (Zhang et al. 2012).
Massively parallel sequencing (MPS) allows simulta-
neous analysis of the complete mtDNA and provides
annotation and mutant load estimation of each position.
Taking into account the variable sequencing depth of
published data, small sample sizes, read mapping and data
filtering criteria, and heteroplasmy detection thresholds,
there is no consensus of opinion as regards average het-
eroplasmic frequency distribution among individuals and
in populations. Full-length mtDNA analysis from 131
individuals identified 40 point heteroplasmies and indels at
10 % minor allele frequency (MAF) or higher in blood or
saliva, making 0.3 heteroplasmies per individual (Li et al.
2010). In contrast, 1.8 heteroplasmies per individual at
[10 % MAF were identified using 40 immortalized lym-
phoblastoid cell line samples (Sosa et al. 2012). In recent
reports (Andrew et al. 2011; Goto et al. 2011; Avital et al.
2012), variable heteroplasmy in the human body has been
demonstrated to exist within a limited number of tissues
such as blood, skeletal muscle and buccal epithelium,
leaving the rest of the organism out of focus. As multiple
tissue analysis in healthy individuals is highly complicated,
data on whole body mtDNA heteroplasmy is still far from
clear.
In this study, we were able to investigate three
unrelated males by employing MPS technology to detect
mtDNA heteroplasmy using 16 different tissues
taken during post-mortem examination. We show a great
range of heteroplasmy variance at position 16,093,
where the lowest values were detected in red and yellow
bone marrow tissue and the highest in the bladder. The
data contribute to mtDNA genetics at human body level
and explain the possible formation and expansion of
heteroplasmy during post-zygotic embryonic
development.
Methods
The Research Ethics Committee of the University of Tartu
approved the collection of tissue samples for research. The
written informed consent was obtained from next-of-kin to
post-mortem individuals to collect the tissue panel during
the autopsy. Encoded body panel was collected from three
males of 40 (sample KT538), 53 (KA522) and 54 (SJ600)
years of age at the time of death. Donors KT538 and
KA522 had died of acute cardiovascular insufficiency due
to myocardial infarction and SJ600 of cerebellar haemor-
rhage. The tissue samples were collected within 8 h of
post-mortem and consisted of abdominal adipose tissue,
lienal artery, bone, yellow bone marrow, red bone marrow,
coronary artery, gastric mucosa, joint cartilage, thoracic
lymph node, tonsils, bladder, gall bladder, abdominal aorta,
thoracic aorta, medulla oblongata and nervus ischiadicus
(Table 1). DNA extraction was carried out according to the
recommendations of the NucleoSpin Tissue DNA extrac-
tion kit manufacturer (Macherey-Nagel, Du¨ren, Germany),
with DNA concentrations and quality parameters provided
in Supplementary Table 1. Four anonymous genomic DNA
samples for replication sequencing were provided by the
Estonian Genome Center of the University of Tartu (EGC).
Whole mtDNA was amplified in two amplicons (8,225 and
9,447 bp) by PCR using two pairs of primers. PCR
amplicons were enzymatically fragmented, prepared as a
48-plex sequencing library and analysed using an Illumina
HiSeq2000 instrument with 101 bp paired-end reads
according to the manufacturer’s protocols. Confirmation of
mtDNA position 16,093 heteroplasmic samples and the
300–320 D-loop region in three individuals was performed
by Sanger sequencing. The data were analysed using freely
available software. All details of methods used are pro-
vided in Supplementary Methods.
Results
A total of 260 million paired-end reads were generated for
16-tissue body panels in three unrelated males (48 samples
in total) and for four replicates (8 samples). Each sample
library preparation was started from 0.5 ± 0.1 lg of PCR
product, but demultiplexing revealed 22-fold differences
between sample raw reads (Supplementary Fig. 1). Map-
ping and read trimming increased it to 49-fold, but quality
score-based filtering and PCR duplicate removal finally
reduced sample variability to 25-fold. The post-filtering
mean quality score was 33.5 and 84 % of reads (median)
had a quality score of C30. 80.2 % (median) of reads
mapped to mtDNA reference and 41.5 % of reads (median)
were removed afterwards during the PCR duplicate filter-
ing step. The average MAF fraction over the full mtDNA
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sequence is \0.15 % (Supplementary Table 2). PCR
amplification generated unequal coverage over mtDNA,
preferring one amplicon to another and bringing out two
overlapping regions in amplicons (Fig. 1a). In KA522, the
joint cartilage tissue sample was removed as a result of
low-sequencing coverage and quality, caused by lower
(p = 0.0003) purity of the original DNA sample (Supple-
mentary Table 1).
Forty-seven samples were mapped against a reference
sequence to investigate heteroplasmy in mtDNA. Pre-
liminary analysis revealed heteroplasmy with MAF of
\10 % at mtDNA positions 302, 309, 310, and 316 in the
three studied DNA body panels but Sanger resequencing of
poly-C tracks in mtDNA bases 302–310 and 312–317
showed no heteroplasmy in this region, and confirmed only
KT538 C insertion at mtDNA position 309 (named
C309CC, Supplementary Fig. 2). That demonstrates that
MPS mapping output needs Sanger confirmation under
these conditions. The significant heteroplasmy ([10 %)
was detected only in individual SJ600 at D-loop position
16,093 (m.16093T [ C) (Fig. 1b). Red and yellow bone
marrow had 5.1 and 8.9 % heteroplasmy, respectively.
Abdominal aorta, thoracic aorta, coronary artery and lienal
artery clustered as one group and showed heteroplasmy in
the range of 31.2–50.9 %, while 62.0 % mtDNA hetero-
plasmy was detected in the bladder (Table 1). Three tissues
with variable heteroplasmy of 5–50 % were examined in
detail and confirmed by independent Sanger sequencing
(Fig. 1c–d). Two other individuals (KT538 and KA522)
had no heteroplasmy at position 16,093.
Four blood DNAs from the EGC were analysed as
duplicates to show the assay reproducibility. The median
sequencing depth of all eight samples varied from 4,832 to
11,531 and at least 99.5 % of all the nucleotides had
[1,000 fold sequencing depth (Supplementary Table 3). In
total, eight heteroplasmic positions were detected at [5 %
MAF. Heteroplasmic MAF variance between the replicates
was 1.5–25.8 % and the correlation coefficients were
0.88–0.99 (Supplementary Fig. 3).
Discussion
mtDNA is highly represented in somatic cells, making it as a
considerable DNA source after nuclear DNA. Nevertheless,
the ‘‘total length’’ of mtDNA per cell is up to 20 Mb, which is
still 400 times less than the amount of diploid nuclear DNA
and therefore mtDNA needs specific enrichment before the
MPS analysis. Despite the success of capture-probe-based
mtDNA enrichment (Li et al. 2012), PCR is still the ‘‘gold
standard’’ for selection and amplification of small, targeted
DNA regions, like mtDNA. In addition, the results indicate
that PCR-introduced errors should not be a significant prob-
lem as regards this approach (Li et al. 2010; Zaragoza et al.
2010). We used 22 PCR cycles to reduce possible bias accu-
mulation and ensured an efficient PCR yield with 0.2–1.2 lg
of input DNA. The size-selected library was repaired and
amplified using ten additional cycles, which were too intense
because 41.5 % of mapped reads were eliminated during PCR
duplicate filtering (Supplementary Fig. 1).
Table 1 Heteroplasmy overview at position 16,093 of individual SJ600
Tissue Sequencing depth Major allele Ca Minor allele Ta MAF (%)
Bladder 12,339 C 4,691 Tb 7,645 62.0
Lienal artery 5,343 C 2,625 Tb 2,717 50.9
Coronary artery 17,265 C 11,123 Tb 6,139 35.6
Thoracic aorta 6,870 C 4,446 Tb 2,422 35.3
Abdominal aorta 9,828 C 6,762 Tb 3,061 31.2
Nervus ischiadicus 8,391 C 6,190 Tb 2,200 26.2
Gall bladder 5,433 C 4,041 Tb 1,391 25.6
Bone 11,603 C 9,047 Tb 2,555 22.0
Gastric mucosa 11,954 C 9,692 Tb 2,222 18.6
Abdominal adipose tissue 3,724 C 3,039 Tb 685 18.4
Medulla oblongata 12,985 C 11,266 Tb 1,717 13.2
Thoracic lymph node 14,600 C 12,672 Tb 1,926 13.2
Tonsils 10,827 C 9,752 Tb 1,073 9.9
Joint cartilage 14,444 C 13,074 Tb 1,368 9.5
Yellow bone marrow 18,223 C 16,607 Tb 1,613 8.9
Red bone marrow 11,650 C 11,051 Tb 598 5.1
a Allele read count
b The reference allele according to the revised Cambridge reference sequence (rCRS)
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The heteroplasmy threshold is an important parameter
for accurate detection of heteroplasmy. The threshold cal-
culations based on nuclear DNA control libraries demon-
strated that the average proportion of mutations per base
was 0.06 % and no base was mutated at greater than 0.8 %
frequency (He et al. 2010). A similarly low threshold
(1.3 %) was reported using synthetic DNA fragments with
variable allelic ratios (Zhang et al. 2012), providing the
acceptable 5–10 % cut-off for heteroplasmy (Li et al. 2010;
Sosa et al. 2012). At the same time, attention should be
paid to the fact that artificial quality control DNAs are only
useful for assessing indexed library amplification, cluster
generation and MPS itself, but are not suitable for sample
enrichment and DNA quality issues. In our study, the
detected variability at position 16,093 was confirmed by
Sanger sequencing at 5, 22 and 51 % MPS-detected het-
eroplasmy levels. As expected, 5 % heteroplasmy is not
detectable by dideoxy-terminator sequencing, 22 % het-
eroplasmy remains unquantified, and 51 % heteroplasmy
correlates as a 1:1 polymorphic allelic ratio (Fig. 1d). As
our experiment was designed without internal controls to
detect the MPS sensitivity threshold, we are not able to
report the number of true-positive heteroplasmies without a
confirmation experiment. Nevertheless, we detected a great
range of position 16,093 heteroplasmy in the human body,
contributing to a previous multi-tissue analysis (He et al.
2010). In that previous study, somatic heteroplasmy rang-
ing 7–91 % was found in one of the two study patients.
However, the authors studied significantly fewer tissue
samples from the same autopsy individual, with little
overlap to the panel used in our study. Furthermore,
colorectal cancer as the cause of death in (He et al. 2010),
could influence the extent of somatic heteroplasmy.
Unfortunately our analysed tissues did not include blood
samples, but according to other recent reports reflecting
low-level heteroplasmy in blood (Andrew et al. 2011;
Avital et al. 2012; Payne et al. 2012), we can speculate that
blood (leukocytes) may have lower heteroplasmy level
Fig. 1 Full mtDNA amplification and the confirmation of results.
a mtDNA was amplified using two overlapping PCR products, blue
and red circles. Average coverage density is shown (green).
b Position 16,093 heteroplasmy over the SJ600 body panel.
c Sequencing coverage in hypervariable region (HVRI) of D-loop.
Coverage in the three different tissues of individual SJ600 is shown.
d Sanger sequencing confirmation of position 16,093 heteroplasmy.
The percentage is from MPS analysis and chromatogram from Sanger
sequencing
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than the rest of human body. Because red bone marrow
consists mainly of hematopoietic tissue giving rise to all
blood cell types, we used red bone marrow (heteroplasmy
5.1 %) as a possible alternative to blood in our study. Also,
it is suggested that rapidly dividing tissues such as blood
cells or bone marrow may have the ability to eliminate
cells with mtDNA mutations during life, whereas ‘‘post-
mitotic’’ tissues that no longer divide do not eliminate these
cells and may instead favour accumulation of mutant
mtDNA genomes. Hence, this could clarify why some
inherited mtDNA mutations can be lost from the blood but
be detected in other post-mitotic tissues (Payne et al. 2012).
Our findings are in line with this, demonstrating very low
frequency of heteroplasmy in rapidly dividing red and
yellow bone marrow tissues, with 5 and 9 % of hetero-
plasmy, respectively.
According to our findings, position 16,093 was hetero-
plasmic in all 16 studied tissues in one individual, varying
from 5.1 % in red bone marrow to 62.0 % in the bladder.
The differences between organ groups can be explained by
random segregation of mtDNA during oogenesis and in
somatic tissue development. It is now believed that somatic
segregation may lead to high levels of mutant mtDNA in
some progenitor cells and low levels in others. In addition,
due to the high copy number of mtDNAs, a mutation in
some of the mtDNA results in a mixture of variant mito-
chondrial genomes within a mitochondrion, cell, tissue,
organ, or individual. However, it is impossible to predict
the cell types or tissues to which mutant molecules will
segregate during the ontogenesis. It is likely that such
heteroplasmic variability in our study is a result of random
genetic drift and not strongly associated with certain
developmental stages or tissue differentiation processes.
These findings could explain the unequal distribution of the
different genotypes, not only between the three germinal
layers (endoderm, mesoderm and ectoderm), but also
between derivatives of the same germinal layer. In our
panel that mostly contains tissues of mesodermal origin,
heteroplasmy at position 16,093 differed by more than
40 % between two mesodermal derivatives—bone marrow
and lienal artery. In contrast, the same heteroplasmic fre-
quency (9 %) was present in tissues of different origin,
such as tonsils and joint cartilage, which are of endodermal
and mesodermal origin, respectively. Interestingly, our
results clearly demonstrated similar high-heteroplasmic
frequency in various blood vessels—abdominal aorta,
thoracic aorta, coronary artery and lienal artery, ranging
31–51 %. Arteries carry oxygenated blood away from the
heart to the tissues that require oxygen. These findings may
partially be interpreted by the production of oxygen radi-
cals during oxidative phosphorylation and common meso-
dermal origin. The fact that in bladder tissue we observed
the highest frequency of heteroplasmy could be explained
by its tissue-specific prevalence, as also indicated by the
high incidence of mtDNA mutations in bladder cancer
(Guney et al. 2012).
In conclusion, our results demonstrate that screening of
a tissue panel using MPS technology provides surprising
data that reveals somatic heteroplasmy even among the
limited number of study subjects. Our findings give clear
reason to speculate that mtDNA heteroplasmic frequency,
distribution, and even its possible role in complex diseases
or phenotypes could be severely underestimated, evoking
the need for more thorough tissue-based screenings at
different age groups to provide more comprehensive
understanding about its biological and clinical importance.
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